Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bill Gates invests USD...

    Bill Gates invests USD 140 million in HIV cure

    Written by supriya kashyap kashyap Published On 2017-01-05T12:41:04+05:30  |  Updated On 5 Jan 2017 12:41 PM IST
    Bill Gates invests USD 140 million in HIV cure

    Houston : Microsoft founder Bill Gates' charity foundation has invested USD 140 million in the development of HIV preventing drug implants that could revolutionise the treatment of the life-threatening infection.


    The Bill and Melinda Gates Foundation is providing this funding for the groundbreaking new technology which could revolutionise HIV prevention.


    Currently prevention drugs are available in the form of a pill that, if taken daily, can reduce a person's chances of being infected with HIV.


    The drugs are recommended by the World Health Organisation for use by at-risk groups including men who have sex with men but are only effective if the pills are taken consistently.


    There are hopes that implant technology, similar to systems available for birth control, could be used to deliver a consistent supply of drugs, aiding people vulnerable to HIV.


    According to The Wall Street Journal, their latest investment has placed their backing firmly behind a bio-pharmaceutical company located in Boston. They believe that this company could yield one of the largest revelations in HIV treatment yet.


    This treatment takes the form of a pump that was initially designed for type two diabetes patients. It works by continuously delivering medication throughout the body. The pump is reportedly capable of administering drugs throughout the body for as long as 12 months. It could also be easily filled by a clinician annually or bi-annually.


    Researchers believe that the pump could work similarly, for HIV prevention, in healthy patients. Delivering treatment such as PreP continuously and, therefore, working to prevent HIV and AIDS. PreP is a daily drug that has been critical in preventing HIV infections in sexually active adults.


    The Gates invested USD 50 million in equity stakes at Intarcia Therapeutics the company responsible for the pump. They then provided a further USD 90 million in company grants towards the goal of developing the HIV preventing device.

    AIDSBill and Melinda Gates FoundationBill GatesHIVHIV treatmentInvestmentWall Street JournalWorld Health Organisation
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok